Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with ...

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...

Editas, one of the oldest CRISPR-focused biotechs, is pivoting again — to a sickle cell treatment that requires editing a ...

Find Latest News, Videos and Pictures about CRISPR. Explore latest updates, news, information from NewsBytes. All about CRISPR.

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

Early data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such ...

EDT Cathie Wood’s ARK Investment bought 47.8K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...

CRISPR Therapeutics AG (CRSP) closed the last trading session at $48.92, gaining 1.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jack Allen ...

CRISPR technology allows for precise DNA modifications, holding promise for treating genetic disorders and revolutionizing ...

An editorial by Fyodor Urnov lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.